New & Better Test for Peanut Allergy
Synopsis: New peanut allergy test capable of determining potential intensity of an allergic reaction through just a few drops of blood.1
Author: University of Connecticut Contact: Colin Poitras - firstname.lastname@example.org
Published: 2015-02-27 Updated: 2016-03-23
Current peanut allergy tests are not very reliable when it comes to diagnosing the severity of an individual's allergic reaction, which can range from hives to life-threatening anaphylactic shock.
A type of food allergy due to peanuts. It is different from nut allergies. Physical symptoms of allergic reaction can include mild itchiness, urticaria, swelling, eczema, sneezing, asthma, abdominal pain, drop in blood pressure, cardiac arrest and anaphylaxis. The exact cause of someone developing a peanut allergy is still unknown.
Anaphylaxis (Anaphylactic Shock)
Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. It typically causes a number of symptoms including an itchy rash, throat swelling, and low blood pressure. Common causes include insect bites and stings, foods, and medications. In severe cases, a person will go into shock. If anaphylactic shock isn't treated immediately, it can be fatal. As many as one-third of peanut-sensitive patients have severe reactions, such as fatal and near-fatal anaphylaxis. ("Anaphylactic deaths in asthmatic patients," Allergy Proc., 1989)
With an estimated three million people in the United States allergic to peanuts and tree nuts, having a more precise and reliable allergy test could prevent hospitalizations and allow for better monitoring of individuals suffering from peanut allergies.
Three chemists at the University of Connecticut (UConn) are developing a more advanced peanut allergy test that, based on initial results, is many times more sensitive than current procedures. The new test is capable of determining the potential intensity of a patient's allergic reaction through just a few drops of blood.
Understanding how the new test works requires a basic understanding of how allergic reactions happen. When an allergic person eats peanuts, their immune system releases an antibody protein known as immunoglobulin E or IgE. These antibodies fight off peanut allergen molecules by binding to them and flushing them out of the body. But the release of the antibodies causes tissue cells in the body to produce histamine, which in turn generates a variety of allergy symptoms such as itchy skin, runny nose, coughing, or wheezing. The more antibodies that are released, the more histamine is generated, the stronger the person's allergic response.
"A patient who has a serious allergy and gets exposed to an allergen protein will form antibodies in their body that should stay there for awhile," says UConn Professor James Rusling, who specializes in detecting protein biomarkers and used a similar process to detect proteins linked to cancer. "Our theory is that the level of those antibodies can be used to predict how severe a patient's allergy is at any one point in time."
While existing peanut allergy tests can generally measure IgE antibodies found in a blood sample, the presence of other biomolecules can distort the results and they are not always accurate.
The allergy test designed by Rusling, Mark Peczuh and Challa Vijaya Kumar screens out other biomolecules and measures the presence of antibodies that bind to very specific protein fragments, called peptides, and carbohydrate residues found in peanuts.
"The traditional method of measuring these antibodies uses a mixture of all the peanut proteins, not individual parts," says Peczuh, a specialist in carbohydrate synthesis whose daughter has a peanut allergy. "But some of the stuff in the mixture can lead to readings that a patient is allergic when she or he is not. And the converse can be true, where the results show someone is not allergic when they actually are."
In the study of their new system, the UConn chemists tested three components from the most potent peanut allergen. One sample was a protein peptide, another a carbohydrate residue, and the third was a positive control.
The chemists then injected blood serum from patients known to have peanut allergies into the array. As the blood serum floated over the samples, IgE antibodies were pulled down by the allergens and bound by them. They could then measure the quantity of antibodies to determine how strong a reaction a person would have to peanuts. To further refine the system, the team attached magnetic beads to the allergen samples. The beads captured the IgEs and amplified the final measurements, allowing them to detect concentrations of antibodies as low as 0.5-1 picogram per milliliter.
The test results correlated with the patients' known allergy levels from other tests and the team was encouraged to pursue further development of the approach.
While the trial test was limited to just a few allergic components from peanut glycoproteins, Rusling says it could be expanded to screen for more than 20, allowing for even more selective results.
Although the initial results are promising, the time frame for any clinical use of the test is still years away.
"Eventually, we'd like to use maybe five different peptides and carbohydrate samples to see how these IgEs bind to them," says Rusling. "That way, we could determine a clear fingerprint of a patient's susceptibility to a specific allergen."
There has been some debate over the role carbohydrates play in allergies. Because the UConn test has the capacity to test both protein peptides and carbohydrate residues, the researchers hope it can be used to learn more about how specific protein and carbohydrate epitopes bind to antibodies to gain a better understanding of how allergies are induced.
"Our hope is that this could be used as an analytical tool to investigate the actual biology of the allergic response to peanuts and other food items in general," says Rusling. "People have noted that certain carbohydrates may be involved in allergies and we'd like to determine whether they are involved or not."
North Carolina Agricultural and Technical State University received a patent in 2012 for a process to reduce allergens in peanuts 98 percent or more. The process treats roasted peanuts, removed from the shell and skin, with food-grade enzymes commonly used in food processing. The treatment consists of soaking the peanuts in an enzymatic solution. The treatment reduces two key allergens, Ara h 1 to undetectable levels and Ara h 2 by up to 98%. The resulting peanuts look and taste like roasted peanuts. The peanuts are not genetically modified.
- About 3.3 million Americans are allergic to nuts.
- The percentage of people with peanut allergies is 0.6% in the United States.
- 150 people (children and adults) die each year from ALL food allergies combined.
- The number of young children self-reporting the allergy doubled between 1997 and 2002.
- In a 2008 study, self-reported incidence of peanut allergy was estimated to affect 1.4% of the population of the United States, triple the 0.4-0.6% rate found in a 1997 study.
- Allergy to peanuts affects 1.3% of the general population. Peanut allergy affects 7 percent of brothers and sisters of persons with the allergy. (British Medical Journal 1996;313:518-521.)
- In England, an estimated 4,000 people are newly diagnosed with peanut allergy per year (11 per day); 25,700 having been diagnosed with peanut allergy by a clinician at some point in their lives.
Related Food Allergy Documents
Full List of Food Allergy Publications Full List of Disabled World News Updates
Recent Disability News and Updates
Full List of Disabled World News Updates
Disclaimer: Disabled World is strictly a news and information website provided for general informational purpose only and does not constitute medical advice. Materials presented are in no way meant to be a substitute for professional medical care by a qualified practitioner, nor should they be construed as such. Please report outdated or inaccurate information to us.
Disclosure: Disabled World is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com. Any 3rd party offering or advertising on disabled-world.com does not constitute endorsement by Disabled World. View our Advertising Policy for further information.